On experimental investigation, it was found that PPARγ suppresses gastric carcinogenesis and that PPARγ ligands such as troglitazone and ciglitazone are potential agents for gastric carcinoma because they inhibit PPARγ-dependant cell proliferation [42–44]. This evidence concerns the gene PPARG and gastric carcinoma.